Company Profile

Zen-Bio Inc (AKA: ZenBio Inc.)
Profile last edited on: 4/30/18      CAGE: 3MZW4      UEI: LQS2WJFBBUQ3

Business Identifier: Metabolic disease therapies
Year Founded
1995
First Award
2003
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3200 East Highway 54 Suite 100
Research Triangle Pa, NC 27709
   (919) 547-0692
   information@zen-bio.com
   www.zen-bio.com
Location: Single
Congr. District: 04
County: Durham

Public Profile

Organized around providing human blood products and cells used in the study of human metabolic disease and skin related disorders, Zen-Bio, Inc. is a privately held biotechnology company providing advanced cell-based solutions and services to the life science, cosmetics, and personal care communities. The company was an early provider of adipose derived stem cells (ASCs). Building on that expertise, the firm also provides cutting edge human primary cell culture products and services. The firm's products include human cell systems, including subcutaneous preadipocytes and adipocytes, visceral preadipocyte and adipocytes, hepatocytes, skeletal muscle, adult stem cells, fibroblasts, keratinocytes, mesothelial, and 3T3-L; media formulations; serum products, such as fetal bovine serum, calf serum, and human blood products; research kits to test compounds for their use in obesity or diabetes therapies, and cellulite or wrinkle treatments; and natural product libraries, including pure compound, plant, and microbial libraries, as well as phytochemicals. Zen skin platform specifically addresses the needs of dermatology researchers: company provides full thickness skin skin equivalence skin derive cells related reagents and contract services to the biomedical research community

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Peter Pieraccini -- President

  Benjamin M Buehrer -- VP

  Bentley B Cheatham -- VP of Research and Development

  Sarah A Compton

  Hayes Heather Hayes

  Renee Lea-Currie -- Director of Cell Biology

  Yolanda R Leacurrie

  John W Ludlow -- Executive Director, Regenerative Medicine

  Jim Nicoll -- Director of Contract Research and Development

  Will Plentl -- Chief Operating Officer

  Kevin P Williams